Traduction de «products shows » (Néerlandais → Français) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat baricitinib bevat
produit contenant du baricitinib

product dat barbituraat bevat
produit contenant du barbiturique

TRADUCTIONS EN CONTEXTE

Within hypertension, Novartis continues to drive sales as the valsartan group of products shows consistent worldwide growth, reaching a market share of 15.7% of the hypertension market segment based on the three months from June to August 2010.
Dans le segment de l'hypertension, les ventes du groupe de produits valsartan de Novartis affichent une croissance continue dans le monde entier. Ce groupe a atteint une part de 15,7% de ce segment de marché au cours des trois mois allant de juin à août 2010.

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus

The successful development and launch of this first-to-market generic shows the ability of Sandoz to broaden its portfolio with complex new differentiated products.
La réussite du développement et du lancement de ce générique, premier sur le marché, montre la capacité de Sandoz à élargir son portefeuille avec de nouveaux produits complexes et différenciés.

In these cases, the necessary authorisations are often lacking (e.g. for production, release of batches, import, wholesale and distribution, distribution within the European Union, export, possession) ●● Internet and distance selling ●● Human and veterinary doping (e.g. bodybuilding, cycling, show-jumping, pigeonracing) ●● Veterinary crime relating to veterinary medicines (e.g. abuse of antibiotics) ●● Crime and fraud within GCP, GDP, GMP,
In these cases, the necessary authorisations are often lacking (e.g. for production, release of batches, import, wholesale and distribution, distribution within the European Union, export, possession) ●● Internet and distance selling ●● Human and veterinary doping (e.g. bodybuilding, cycling, show-jumping, pigeonracing) ●● Veterinary crime relating to veterinary medicines (e.g. abuse of antibiotics) ●● Crime and fraud within GCP, GDP, GMP,